匯隆控股(08021.HK)籤大健康產業生態圈戰略合作協議
匯隆控股(08021.HK)公佈,昨日(27日)與浙江恆婷生物科技簽署戰略合作協議,雙方初步達成於適當時機合作銷售,共同發展或採用其他合作方式於構建全民大健康產業資源創新生態圈,結合各大藥企業產能,大健康基地終端配套以及銷售和產品專業。
雙方將基於長期戰略合作原則開展全面戰略合作,包括但不限於股權投資、債務投資及其他投資方式。雙方將根據市況繼續擴大合作範圍,可能不定期召開高層會議討論合作的模式、方向、進度及其合作專案的其他事宜。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.